Skip to main content
Figure 7 | BMC Gastroenterology

Figure 7

From: Lubiprostone ameliorates the cystic fibrosis mouse intestinal phenotype

Figure 7

Verification of microarray results for selected genes by qRT-PCR. (A) Retnlb, resistin-like β, also known as Fizz2; (B) Chi3l4, chitinase 3-like 4, also known as Ym2; (C) Pla2g4c, phospholipase A2, group 4c; (D) Gsdmc2, gasdermin c2; (E) Mcpt2, mast cell protease 2; (F) Slc5a12, sodium-monocarboxylate transporter; (G) Cyp4a10, cytochrome P450 4a10; (H) HemT1, hematopoietic cell transcript 1; (I) Muc2, mucin 2; (J) Muc3, mucin 3. All data are normalized to expression of ribosomal protein 26 (Rpl26) and are relative to WT control expression levels. Data are means ± SEM; *: P <0.05 comparing CF control to WT control; +: P < 0.05 +Lubi compared to control of same genotype. (n = 8 WT controls, 6 WT lubiprostone treated, 8 CF controls, 6 lubiprostone treated CF samples)

Back to article page